| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Endocrinology, Bradford Hospitals National Health Service Trust (S.R.P.), Bradford, United Kingdom BD9 6RJ; Department of Endocrinology, Christie Hospital (S.M.S.), Manchester, United Kingdom M20 4BX; and Department of Medicine, University of Virginia Health Sciences Center (A.A.T., J.D.V., M.O.T.), Charlottesville, Virginia 22908
Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital, Wilmslow Road, Manchester, United Kingdom M20 4BX.
In patients with treated acromegaly, improved survival is associated with serum GH concentrations below 2 µg/L (5 mU/L). A principal aim of therapy in acromegaly is to achieve a GH level less than 2 µg/L, as such levels are thought to be "safe." However, such GH levels do not always equate with normalization of plasma insulin-like growth factor I (IGF-I), although epidemiological data linking survival or morbidity to IGF-I levels are at present lacking. The aims of this study were 1) to further define the nature of GH release in those acromegalic patients who achieve mean GH concentrations below 2 µg/L post therapy, 2) to examine the effect of different therapeutic interventions on the 24-h GH profile (surgery alone or radiotherapy), and 3) to determine the relationship between the various characteristics of the 24-h GH profile and IGF-I production in acromegalic subjects who have achieved GH below 2 µg/L. Spontaneous 24-h GH secretion was measured using both a conventional immunoradiometric assay (limit of detection, 0.4 µg/L) and an ultrasensitive assay (limit of detection, 0.002 µg/L). The GH data have been analyzed by several methods: 1) the pulse detection algorithm Cluster, 2) a distribution method for detection of peak [the observed concentration 95%, i.e. the threshold at or below which GH concentrations are assessed to be 95% of the time, as calculated by probability analysis (OC 95%)] and trough (OC, 5%) GH activity, 3) deconvolution analysis, and 4) approximate entropy analysis. GH was sampled every 20 min for 24 h, along with basal IGF-I and IGF-binding protein-3, in 21 treated acromegalic patients with a mean GH below 2 µg/L [ACR; 9 women and 12 men; median age (range), 49 (31–76) yr] and 16 healthy controls [C; 6 women and 10 men; age, 50 (30–75) yr]. Mean 24-h serum GH concentrations were [median (range)]: ACR, 1.1 (0.04–1.5) µg/L; C, 0.4 (0.02–3.3) µg/L (P = 0.28). GH pulse frequency was: ACR, 11 (1–14)/24 h; C, 10 (8–18)/24 h (P = 0.41). In the GH profiles the mean heights of the GH peaks were: ACR, 1.2 (0.05–2.8) µg/L; C, 0.8 (0.02–5.1) µg/L (P = 0.91), and the mean GH valley nadirs were: ACR, 0.65 (0.03–1.1) µg/L; C, 0.09 (0.01–1.8) µg/L (P < 0.02). The OC 95% was: ACR, 1.0 (0.04–3.8) µg/L; C, 1.0 (0.02–10) µg/L (P = 0.65), and the OC 5% was: ACR, 0.09 (0.01–0.6) µg/L; C, 0.01 (0.001–0.4) µg/L (P < 0.001). The median IGF-I was: ACR, 227 (100–853) µg/L; C, 156 (89–342) µg/L (P < 0.005). Approximate entrophy values were: ACR, 1.06 (0.35–1.45); and C, 0.57 (0.27–1.19); P < 0.05.
In the acromegaly group a significant positive correlation was found
between IGF-I and the calculated GH secretory burst amplitude in the
radiotherapy subset (r = 0.85; P < 0.0005) as
well as between IGF-I and both the mean GH valley nadir (r = 0.60;
P < 0.004) and the trough (OC 5%) GH activity for
the acromegalic patients as a whole (r = 0.55;
P < 0.02). We conclude that in treated acromegaly
(GH, <2 µg/L), 1) IGF-I (by 
50%) and basal GH secretion (by
5-fold) remain significantly elevated compared with control values
despite similar mean 24-h GH concentrations; 2) the calculated GH
secretory pulse amplitude, mean GH valley nadir, and OC 5% correlate
positively with IGF-I; 3) the greater mean GH valley nadir and OC 5%
in acromegalic patients compared with controls may account for the
raised IGF-I; and 4) radiotherapy is unlikely to normalize the GH
secretory pattern, which underlies the persisting elevated IGF-I
levels.
This article has been cited by other articles:
 |
|
 |
|
  K Mullan, C Sanabria, W P Abram, E M McConnell, H C Courtney, S J Hunter, D R McCance, H Leslie, B Sheridan, and A B Atkinson Long term effect of external pituitary irradiation on IGF1 levels in patients with acromegaly free of adjunctive treatment Eur. J. Endocrinol., October 1, 2009; 161(4): 547 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N. G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy Eur. J. Endocrinol., April 1, 2009; 160(4): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sherlock, E. Fernandez-Rodriguez, A. A. Alonso, R. C. Reulen, J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, A. Bates, and P. M. Stewart Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1255 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kamenicky, S. Viengchareun, A. Blanchard, G. Meduri, P. Zizzari, M. Imbert-Teboul, A. Doucet, P. Chanson, and M. Lombes Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in Acromegaly Endocrinology, July 1, 2008; 149(7): 3294 - 3305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Alexopoulou, M. Bex, R. Abs, G. T'Sjoen, B. Velkeniers, and D. Maiter Divergence between Growth Hormone and Insulin-Like Growth Factor-I Concentrations in the Follow-Up of Acromegaly J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1324 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Parkinson, P. Burman, M. Messig, and P. J. Trainer Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF]
|
|
|
|
|
|
A A van der Klaauw, A M Pereira, S W van Thiel, J W A Smit, E P M Corssmit, N R Biermasz, M Frolich, A Iranmanesh, J D Veldhuis, F Roelfsema, et al. GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. Eur. J. Endocrinol., June 1, 2006; 154(6): 851 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Ayuk and M C Sheppard Growth hormone and its disorders Postgrad. Med. J., January 1, 2006; 82(963): 24 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1972 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nomikos, M. Buchfelder, and R. Fahlbusch The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure' Eur. J. Endocrinol., March 1, 2005; 152(3): 379 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.M. Shalet Biochemical Monitoring of Disease Activity after Surgery for Acromegaly J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 492 - 494. [Full Text] [PDF]
|
|
|
|
|
|
P. U. Freda, A. T. Nuruzzaman, C. M. Reyes, R. E. Sundeen, and K. D. Post Significance of "Abnormal" Nadir Growth Hormone Levels after Oral Glucose in Postoperative Patients with Acromegaly in Remission with Normal Insulin-Like Growth Factor-I Levels J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 495 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Clemmons, K. Chihara, P. U. Freda, K. K. Y. Ho, A. Klibanski, S. Melmed, S. M. Shalet, C. J. Strasburger, P. J. Trainer, and M. O. Thorner Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4759 - 4767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly Endocr. Rev., October 1, 2002; 23(5): 623 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Trainer Acromegaly--Consensus, What Consensus? J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3534 - 3536. [Full Text] [PDF]
|
|
|
|
|
|
E. V. Dimaraki, C. A. Jaffe, R. DeMott-Friberg, W. F. Chandler, and A. L. Barkan Acromegaly with Apparently Normal GH Secretion: Implications for Diagnosis and Follow-Up J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3537 - 3542. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
